▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / UPC

UPC — Universe Pharmaceuticals INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1809616 ·
Last close
$2.61
Market Cap
$1.65M
52W High
$3.45
52W Low
$2.00
ADV30
11,993
Next earnings
—
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 — — — — 69,303,440 33,592,025 13,173,930
Mar 2025 — — — — 80,667,159 47,272,851 25,482,206
Sep 2024 — — — — 67,953,393 29,497,693 22,450,452

Balance + Analyst (yfinance extras)

Retained Earnings
$-13,843,623
Inventory
$2,193,179
Receivables
$13,186,018
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$17,858,732
EBITDA
$-2,398,488
Free Cash Flow
$-10,243,885
Enterprise Value
$-22,712,692
Total Cash
$33,592,024
Total Debt
$9,256,919
Shares Out
631,761
Trailing EPS
$-8.06
Book Value
$99.64
ROE
-7.2%
ROA
-2.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 17,858,732 -2,915,919 -3,672,055 69,303,440 13,173,930 — -5,052,319
Sep 2024 23,024,458 -8,019,840 -8,727,298 67,953,393 22,450,452 — -9,506,683
Sep 2023 32,308,735 -3,966,101 -6,581,024 41,724,482 13,754,329 — 1,116,775
Sep 2022 40,143,151 -7,019,444 -7,909,638 59,539,875 13,097,552 — -1,301,555
Sep 2021 — — — — — — —

Peers — same industry

TickerNameMarket CapLastDaily %
CLSDQ Clearside Biomedical, Inc. $1.65M $0.31 —
PCYN PROCYON CORP $1.64M $0.20 —
JAGX Jaguar Health, Inc. $1.60M $3.11 —
AXIM AXIM BIOTECHNOLOGIES, INC. $1.80M $0.01 —
ZVSA ZyVersa Therapeutics, Inc. $1.46M $0.18 —

News headlines (Yahoo Finance, 1h cache)

Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure
2026-02-11 21:05 · Yahoo
Universe Pharmaceuticals Reports First Half 2025 Earnings
2025-07-08 10:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →